OncologyAstraZeneca
AstraZeneca Reports Phase 3 HIMALAYA Results for Imfinzi Plus Tremelimumab in Liver Cancer
BMI
Biotechnology Media Insights
Editorial Team · October 12, 2023
AstraZeneca announces Phase 3 HIMALAYA trial results showing STRIDE regimen significantly improves overall survival in unresectable hepatocellular carcinoma.
AstraZeneca today announced results from the Phase 3 HIMALAYA trial evaluating the STRIDE regimen (single tremelimumab dose plus Imfinzi) versus sorafenib in patients with unresectable hepatocellular carcinoma. The trial met its primary endpoint, demonstrating a significant improvement in overall survival with the STRIDE regimen.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.